Advertisement
Singapore markets closed

  • Straits Times Index

    3,280.10
    -7.65 (-0.23%)
     

  • Nikkei

    37,934.76
    +306.28 (+0.81%)
     

  • Hang Seng

    17,651.15
    +366.61 (+2.12%)
     

  • FTSE 100

    8,122.79
    +43.93 (+0.54%)
     

  • Bitcoin USD

    63,987.07
    +840.12 (+1.33%)
     

  • CMC Crypto 200

    1,384.60
    -11.93 (-0.85%)
     

  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     

  • Dow

    38,085.80
    -375.12 (-0.98%)
     

  • Nasdaq

    15,611.76
    -100.99 (-0.64%)
     

  • Gold

    2,361.40
    +18.90 (+0.81%)
     

  • Crude Oil

    84.15
    +0.58 (+0.69%)
     

  • 10-Yr Bond

    4.6650
    -0.0410 (-0.87%)
     

  • FTSE Bursa Malaysia

    1,575.16
    +5.91 (+0.38%)
     

  • Jakarta Composite Index

    7,036.08
    -119.22 (-1.67%)
     

  • PSE Index

    6,628.75
    +53.87 (+0.82%)
     

How Analysts Rate Regenxbio and Peers in April 2018

Kenneth Smith
Updated
How Analysts Rate Regenxbio and Peers in April 2018

Regenxbio (RGNX) is a clinical-stage biotechnology company focused on developing gene therapy product candidates to address genetic defects. The company’s product candidate RGX-314 is designed for the treatment of wet age-related macular degeneration (or wet AMD), which is a leading cause of total and partial vision loss in the US, Europe, and Japan. The other promising product candidate in Regenxbio’s pipeline is RGX-501 for the treatment of homozygous familial hypercholesterolemia (or HoFH).

Continue reading